Statin vs. Supplements: What the SPORT Trial Actually Found

A low dose of rosuvastatin lowered LDL cholesterol far more than six popular supplements in a direct randomized trial. Over 28 days, rosuvastatin 5 mg produced a placebo-adjusted LDL-C reduction of 35.2 percentage points (95% CI, −41.3% to −29.1%; P<0.001). Fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice did not significantly reduce LDL-C versus placebo.

That result does not prove every supplement is useless. It does answer a narrower and more practical question: can products sold for "cholesterol support" substitute for a low starting dose of a prescription statin in people who need meaningful LDL-C reduction? In this trial, they did not.

A rare direct comparison

The SPORT trial, published by Laffin et al. in 2023, randomized 190 adults to eight groups: rosuvastatin 5 mg, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice. Participants had elevated 10-year cardiovascular risk, LDL-C between 70 and 189 mg/dL, and no established atherosclerotic cardiovascular disease. This is a primary-prevention population: people deciding whether to address elevated cholesterol before a heart attack or stroke forces the issue.

The study was single-center and single-blind, and treatment lasted 28 days. Its primary endpoint was change in LDL-C, a biomarker rather than a measure of heart attacks, strokes, or survival. Still, LDL-C is a well-established treatment target, and the comparison was unusually clean: the statin and supplements were tested under the same trial conditions.

Rosuvastatin beat placebo by 35.2 percentage points and outperformed each supplement under the trial's prespecified hierarchical analysis, with P<0.001 for each statin-versus-supplement comparison. Adverse-event rates were comparable across the eight groups during the 28-day study.

The publication's abstract does not provide reliable per-arm LDL-C effect estimates for each supplement. So the defensible summary is not a made-up leaderboard of tiny wins and losses. It is simpler: none of the six reached statistical significance versus placebo, while rosuvastatin produced a large and precisely estimated relative reduction.

What the trial can—and cannot—settle

SPORT gives rosuvastatin a decisive win over the specific supplement products and doses tested over four weeks. It cannot establish that every formulation of every ingredient has zero LDL-C effect. With roughly 24 people per group, the study had limited ability to detect small changes. A 5% to 10% LDL-C reduction can matter at the population level, but it can disappear into ordinary biological variation in a small, short trial.

That distinction matters most for plant sterols and red yeast rice. A 2021 systematic review of randomized-trial reviews concluded that dietary components and supplements generally produce modest, heterogeneous, dose-sensitive LDL-C effects. SPORT's null results fit that broad pattern, but they do not erase better evidence for every individual product.

Nor does a 28-day test treat every intervention equally. Rosuvastatin reaches steady state within roughly one to two weeks. Some nutritional interventions may require more time, and the trial abstract does not report the dose or formulation details needed to judge whether plant sterols reached an effective threshold or whether red yeast rice contained a meaningful amount of monacolin K.

SPORT tested whether these supplements could match a low-dose statin over 28 days. It did not test whether a well-formulated supplement can produce a smaller LDL-C change over a longer period.

Plant sterols have the strongest case

Plant sterols are the exception worth taking seriously. The DESCO randomized clinical study discusses a meta-analysis of 13 randomized trials in which plant sterols reduced LDL-C by a mean 12.14 mg/dL (95% CI, 8.98 to 15.29 mg/dL). Effects were largest at doses of at least 2 g per day and among people whose baseline LDL-C exceeded 140 mg/dL. European regulators authorize a health claim for plant sterols at 1.5 to 3 g per day.

That is a real effect, not decorative nutrition marketing. It is also a different magnitude from SPORT's 35.2 percentage-point placebo-adjusted result with rosuvastatin. Because one figure is an absolute change in mg/dL and the other is a placebo-adjusted relative change, they cannot be converted into a precise head-to-head ratio. The practical conclusion still holds: plant sterols can be a reasonable adjunct for LDL-C, especially at an evidence-based dose, but the evidence does not support treating them as a replacement for indicated statin therapy.

Red yeast rice is not a harmless workaround

Red yeast rice deserves a separate warning label. Its active compound, monacolin K, is pharmacologically identical to lovastatin, an HMG-CoA reductase inhibitor. In a double-blind randomized trial, a product combining Lactoplantibacillus probiotic strains with monacolin K significantly lowered LDL-C compared with placebo. Because that intervention combined ingredients, the trial cannot isolate the effect of monacolin K alone.

SPORT's null red-yeast-rice result therefore does not mean the ingredient lacks biological activity. Commercial products can contain widely variable amounts of monacolin K, and the SPORT abstract does not establish whether its product delivered a therapeutic amount. But "natural" does not make this a risk-free substitute for prescription care. If a red yeast rice product provides active monacolin K, it can carry lovastatin-like risks, including myopathy and hepatotoxicity, without the consistency of pharmaceutical quality control.

Multi-ingredient nutraceutical trials also report lipid improvements. A 12-week study of a combination containing berberine, red yeast rice, and Morus alba found lipid and vascular changes in people with dyslipidemia, although it enrolled only 33 people and only 26 continued for the longer-term phase. That study cannot show which ingredient drove the result. Other combination trials report favorable lipid findings as well, but industry sponsorship and positive-publication bias can inflate confidence in that literature.

Fish oil is not an LDL-lowering tool

Fish oil failed to significantly lower LDL-C in SPORT, which matches the larger picture. Omega-3 fatty acids do not reliably reduce LDL-C and may modestly raise it in some people. That does not settle every cardiovascular question about omega-3 intake. A review of alpha-linolenic acid, the plant-derived omega-3 found in foods such as walnuts and flaxseed, describes possible cardiovascular benefits through pathways other than LDL-C lowering. A food can have value without becoming cholesterol medication in a capsule.

For garlic, turmeric, and cinnamon, this evidence base does not support clinically meaningful LDL-C lowering. SPORT adds a direct comparison showing that none matched a low-dose statin in this population and time frame.

What clinicians mean by evidence-based

When LDL-C reduction is clinically indicated, the evidence-based menu includes diet, statins, and, when needed, non-statin drugs. Diet still matters: a 2025 review of Mediterranean-diet trials found that Mediterranean patterns supplemented with olive oil or mixed nuts improved cardiovascular risk factors, though it did not establish one as a superior LDL-lowering treatment. Diet changes the background on which every other intervention works.

For people who cannot tolerate statins or do not reach their LDL-C target, prescription alternatives exist. In statin-intolerant patients, bempedoic acid reduced LDL-C by 21% in the analysis reported by Lincoff et al.. PCSK9 inhibitors also substantially lower LDL-C in high-risk patients, according to a 2025 network meta-analysis in acute coronary syndrome. These studies involve different populations and outcome measures than SPORT, so their numbers should not be stacked into a single ranking chart. They do show that evidence-based options extend beyond simply accepting a statin or shopping for substitutes.

The practical verdict

SPORT was small, single-center, single-blind, and short. Those limitations could conceal modest supplement effects, especially for plant sterols and variable red yeast rice products. They do not plausibly turn a 35.2-percentage-point placebo-adjusted LDL-C reduction with rosuvastatin into a tie.

Plant sterols have credible adjunct evidence. Red yeast rice can act like a statin, with the quality-control and safety complications that implies. Fish oil may have purposes unrelated to LDL-C. Garlic, turmeric, and cinnamon are not credible LDL-lowering substitutes. If muscle symptoms or other concerns make a statin difficult, discuss a dose change, another statin, bempedoic acid, or other options with a clinician. The useful question is which combination can achieve your LDL-C target safely—not which bottle looks most medicinal on a kitchen shelf.